TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis - Wikidata - wikimedia - TriplyDB

TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis

TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis

http://www.wikidata.org/entity/Q34792330

about

Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record.Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.Prevalence and microbiological characteristics of clinically infected foot-ulcers in patients with rheumatoid arthritis: a retrospective exploratory study Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis.Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.Increased risk of pneumonia among patients with inflammatory bowel disease.A Fatal Case of Relapsing Pneumonia Caused by Legionella pneumophila in a Patient with Rheumatoid Arthritis After Two Injections of Adalimumab.Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis."Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study".Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.Infectious complications in juvenile idiopathic arthritis.Challenges and approaches for the development of safer immunomodulatory biologics.Rheumatoid arthritis in the elderly in the era of tight control.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Safety issues and concerns of new immunomodulators in rheumatology.Staphylococcus aureus sepsis in rheumatoid arthritis.Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance.Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry.Significant Associations of Neurological Complications of Herpes Zoster With Stroke in Rheumatoid Arthritis Patients.Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.Monoarthritis in a 28-Year-Old Man With Juvenile Idiopathic Arthritis.Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry.Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients.Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis.

P2860

Q33667897-A384AEDB-D088-4A4D-A07C-3E3A15C6C09B Q33778719-A766C7E2-AA1E-4527-8BEF-614F162C6E41 Q33841390-FA3CDC24-E29E-4403-A7B2-AA231EB36477 Q33955217-8829CFB5-54A6-4D71-975E-674EF811B9DE Q35705082-E78B7D16-88C9-4996-B50A-EC1086F00C92 Q35957200-52F69F74-56BF-4563-A413-9A5CE02688C2 Q36099620-04456B4B-1C34-405E-B70C-10AD80916985 Q36191250-FA302015-2BC8-4B6E-B4CA-5EB50FEDC27A Q36219145-2F806426-667C-4D8F-9BDF-D834DD64D8FF Q36981074-213F231F-D5BA-41E2-82B0-7CADB0040F37 Q37189376-EFCD18EF-85A6-4FB2-BC25-E313C63384F0 Q37196596-D02E6924-E511-4158-AE88-518F3FAB8B63 Q37343166-B3403EBF-1D3C-4300-B8F5-D609F556B1A0 Q37358271-F373214A-A0ED-4701-BC97-81A2E3F70DA3 Q37463702-E7490834-52D4-48C0-84D6-4F12890194A7 Q37576833-6BBCC2E6-DA1E-4553-850A-E7BB3760A0C8 Q37729543-56EEBE99-0CFE-435B-A3A0-A07C7C714002 Q38063474-1D0D2214-2F83-4656-BF58-BC6F46112046 Q38093095-FC0B005A-9C65-4D8C-94BA-044D1AB5DC96 Q38093772-FF516CF8-60F9-44D4-A22D-A96650A579F2 Q38150731-848C8968-0EA4-4CC1-B181-2CDA19B61EF8 Q38176745-E8B3D136-CBC8-4472-981A-FD2EDFD05D32 Q38292111-016C929C-4682-4FD2-AC4C-8C1E0B22145A Q38372766-F5575B98-A2D6-4C21-BA86-34E9CB713B93 Q38611360-24149A5D-0B56-452E-8C05-BDC4E18A08C1 Q38827889-C647E420-167A-434E-8671-15357DD8BE5C Q40047193-AE75AC17-0B12-4482-A6D8-C203DFD944BD Q40116120-B4B592D2-4A65-4265-B71E-59ED5F48B2B5 Q40242247-C2CACE79-8883-499B-8333-1A34C5B9EC0B Q40553708-A0CC5252-0286-4A47-89C2-22F2EF02F72D Q41363297-EF0556A8-37CD-4C8B-8D8E-1BCD1A2DAB04 Q41709276-9996A7B4-BAA2-4A11-B0E2-2A6CE7118B59 Q42215038-3B81E658-9A95-48A3-B508-051C596EAF61 Q44518151-7C95B915-768D-4DDE-B15E-4E368233AC50 Q47625115-F1581FD2-6534-40C6-9625-B3B36F900A63

P2860

TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis

http://www.wikidata.org/entity/Q34792330

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

TNF-α antagonist use and risk ...... rans with rheumatoid arthritis

@ast

TNF-α antagonist use and risk ...... rans with rheumatoid arthritis

@en

TNF-α antagonist use and risk ...... rans with rheumatoid arthritis

@nl

type

label

TNF-α antagonist use and risk ...... rans with rheumatoid arthritis

@ast

TNF-α antagonist use and risk ...... rans with rheumatoid arthritis

@en

TNF-α antagonist use and risk ...... rans with rheumatoid arthritis

@nl

prefLabel

TNF-α antagonist use and risk ...... rans with rheumatoid arthritis

@ast

TNF-α antagonist use and risk ...... rans with rheumatoid arthritis

@en

TNF-α antagonist use and risk ...... rans with rheumatoid arthritis

@nl

P1433

Q34792330-89FC8D39-E459-4922-A07F-A2004AED370E

P1476

Q34792330-7D470160-2419-4EB6-90D1-E9D42EBC8E1C

P2093

Q34792330-05D567F3-6C6A-4AD4-88C2-654698CB8A44

Q34792330-0C97EC97-50E7-415C-B0C4-0AE4FBF9E3D3

Q34792330-3A0EC438-38CF-4BDD-BFA0-F326EC2400BF

Q34792330-5AC9277C-3AEB-44DB-B0A6-4D1A12F45448

Q34792330-C379F968-5368-4B40-875A-25D7456CAF3B

Q34792330-E0D34376-7596-4070-93CE-E1F4F4662559

P2860

Q34792330-094CD87D-373C-4AD7-B052-6D94DB65F9BD

Q34792330-14FB8D36-9539-4D39-BCED-F0BBE2959368

Q34792330-1AFE531F-EA7F-4537-927F-5242429DECAC

Q34792330-2A6883DA-404E-4B40-91F0-EDF483EFCDB8

Q34792330-2ABBF7AB-411D-4465-926D-130084278A18

Q34792330-33B14431-EFB2-43DA-A0B2-137003F73669

Q34792330-3C35306E-1423-4AC8-9DBC-407C1A90FD7F

Q34792330-3DFF70ED-BD95-4892-9170-7207232F3802

Q34792330-3F5A5CF2-C4F4-4370-9E53-C555FE712415

Q34792330-4F185F07-DB28-45A8-8CDD-192C9D8993F2

P304

Q34792330-22F67432-095D-4E97-A922-F4ACA5AAE5C7

P31

Q34792330-DFA2EE53-E970-4C5A-9C19-B9F230668C72

P356

Q34792330-FE8AB1BB-E015-4E75-B1F5-22523E90F3F6

P407

Q34792330-04C2A9E4-2A8D-483E-893F-5E045C9A769D

P433

Q34792330-96E54D52-7E7C-4C2C-ABC4-A7A0DC4A29A8

P478

Q34792330-8B92E041-04F4-4431-9E01-6F1259ABBBED

P50

Q34792330-BE6993D6-245E-4DF4-A792-F44AE381CA3C

P577

Q34792330-86F12D90-2316-4618-B7CE-E3081BDA9A7B

P698

Q34792330-AB386ABD-EB69-4172-9595-021A2C3486A2

P921

Q34792330-1C610B1B-1A85-4C5E-B7F7-283FC17F1110

Q34792330-E4CEB16C-A106-496D-90A3-43356E28A215

Q34792330-EE1F076D-35A5-4303-AFA8-2972076407C4

P932

Q34792330-C58D4521-2E9A-4495-A1EE-B3EB79F745CA

P356

MD.0B013E318211106A

P1433

P1476

TNF-α antagonist use and risk ...... rans with rheumatoid arthritis

@en

P2093

Angelique L Zeringue

http://www.w3.org/2001/XMLSchema#string

Jay R McDonald

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Curtis

http://www.w3.org/2001/XMLSchema#string

Liron Caplan

http://www.w3.org/2001/XMLSchema#string

Prabha Ranganathan

http://www.w3.org/2001/XMLSchema#string

Seth A Eisen

http://www.w3.org/2001/XMLSchema#string

P2860

Measuring diagnoses: ICD code accuracy

The incidence of herpes zoster

Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.

Who pays when VA users are hospitalized in the private sector? Evidence from three data sources.

National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data.

Comorbidity measures for use with administrative data.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Mortality in rheumatoid arthritis: 2008 update.

Ten year mortality and causes of death in patients with rheumatoid arthritis.

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

P304

139-145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0B013E318211106A

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P50

Michael A. Lane

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21358439

http://www.w3.org/2001/XMLSchema#string

P921

hospitalization

P932

3076552

http://www.w3.org/2001/XMLSchema#string